HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

In the general population, frailty is an aging-related risk factor for poor outcomes; individuals experiencing frailty face ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...

A bill to ensure NH’s Medicaid program doesn’t pay for circumcisions unless medically necessary was approved by the House by ...

During his address to Congress on March 4, Donald Trump alleged that the Biden administration had spent $8 million "for ...

Measles is unlike other childhood viruses. In severe cases, it can cause pneumonia. About 1 in 1,000 patients develops encephalitis.

Understanding how ... A Chain Reaction: HIV Vaccines Can Lead to Antibodies Against Antibodies Jan. 17, 2025 — Many vaccines work by introducing a protein to the body that resembles part of a virus.